GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will be presenting data demonstrating dramatic reductions in antibody development timelines by enabling large-scale transient gene expression directly within cells commonly used in commercial protein production. The presentation will be made at IBC’s 24th Annual Antibody Engineering and Therapeutics Meeting, held December 8-12, 2013 at the Hyatt Regency Huntington Beach Resort & Spa, CA.
Help employers find you! Check out all the jobs and post your resume.
